Factors associated with efficacy of inucleoside analogues on sequential interferon therapy in HBeAg positive chronic hepatitis B patients
10.3760/cma.j.issn.1003-9279.2019.05.015
- VernacularTitle: HBeAg阳性慢性乙型肝炎核苷(酸)类似物序贯干扰素治疗疗效的相关因素研究
- Author:
Yuanjiao GAO
1
;
Lu ZHANG
;
Yao LU
;
Ge SHEN
;
Shuling WU
;
Hongxiao HAO
;
Min CHANG
;
Leiping HU
;
Minghui LI
;
Yao XIE
Author Information
1. Second Division of Liver Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B, chronic;
Interferon α
-2a;
Nucleoside (acid) analogues;
Hepatitis B surface antigen;
Hepatitis B e antigen
- From:
Chinese Journal of Experimental and Clinical Virology
2019;33(5):513-517
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the factors associated with efficacy of nucleos(t)ide analogues with sequential interferon in HBeAg positive chronic hepatitis B (CHB) patients.
Method:HBeAg positive CHB patients treated with nucleoside analogue (NA) treatment received PEG-IFN α-2a 180 μg subcutaneously once weekly.NA was continually used with PEG-IFNα-2a during the first 12 weeks. HBsAg/HBeAg level and HBV DNA load were observed in the sequential pre-treatment (baseline) period, 12 th, 24 th, 36 th, 48 th and 72 nd weeks of sequential therapy in all patients.
Result:Of the 56 HBeAg-positive CHB patients, 5 (23.1%) achieved HBsAg loss/seroconversion, the baseline HBsAg level in HBsAg loss/seroconversion group was lower than that of the patients in the group that did not achieve HBsAg loss/seroconversion (2.750 lg IU/ml vs. 3.699 lg IU/ml, t=0.955, P=0.000); the difference was statistically significant in HBsAg decreased at the 12 th, 24 th, 36 th, 48 th week in the course of sequential therapy (0.913 vs 0.149, 2.847 vs 0.189, 4.378 vs 0.248, 4.587 vs 0.274 lg IU/ml) (t=-2.950, P=0.040; t=-8.732, P=0.009; t=-8.483, P=0.001; t=-8.214, P=0.003); 11(19.6%) achieved HBeAg loss/ seroconversion, the HBeAg baseline level in HBeAg loss/seroconversion group was lower than the patients in the group that not achieved HBeAg loss/seroconversion (1.217 lgS/CO vs 1.884 lgS/CO, t=2.061, P=0.044); the difference was statistically significant in HBsAg, HBeAg decreased at 24 th, 36 th, 48 th week in the course of sequential therapy between the two groups (1.330 vs 0.205, 2.084 vs 0.258, 1.972 vs 0.284, lg IU/ml; 1.168 vs 0.455, 1.363 vs 0.461, 1.177 vs 0.447, lg S/CO) (t=2.238, P=0.049; t=2.619, P=0.025; t=2.278, P=0.048); (t=2.273, P=0.043; t=3.415, P=0.001; t=2.271, P=0.049).
Conclusions:To HBeAg-positive CHB, lower baseline HBsAg, HBeAg level and HBsAg, HBeAg decreased earlier were could predict easier achievement of HBs(e)Ag loss/seroconversion.
